We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 03, 2021

CV Biomarker Changes With Ertugliflozin in CKD and T2D

Diabetes Care


Additional Info

Diabetes Care
Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
Diabetes Care 2021 Jan 12;[EPub Ahead of Print], PR Lawler, H Liu, C Frankfurter, LE Lovblom, Y Lytvyn, D Burger, KD Burns, D Brinc, DZI Cherney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading